Ardelyx ($ARDX) Drug Access and Revenue Guidance Case
$ARDX investors filed a claim against Ardelyx for allegedly overstating its ability to overcome payer restrictions affecting IBSRELA and XPHOZAH while maintaining revenue and growth targets.
After Ardelyx cut its 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH revenue target, $ARDX fell 17.9% on August 7, 2026.
$ARDX investors can join this case to be notified about potential recovery.
Case Details:
Between January 13, 2025, and August 6, 2026, Ardelyx told investors it expected continued growth for IBSRELA and XPHOZAH and could address patient-access barriers. Executives emphasized improving prescription fulfillment, strong demand, and confidence in the company’s revenue and long-term growth targets.
However, during this period, investors allege increasingly restrictive payer requirements were slowing new-patient starts and hurting XPHOZAH’s long-term growth prospects. Ardelyx allegedly failed to disclose that payers were imposing increasingly restrictive access requirements; stricter prior authorizations and step requirements were slowing new-patient starts and delaying prescriptions, and these barriers threatened the company’s revenue guidance and long-term growth targets.
Then, on August 6, 2026, Ardelyx revealed that increased payer restrictions had hurt IBSRELA revenue, cut its 2026 IBSRELA guidance from $410–$430 million to $350–$370 million, and withdrew its $750 million long-term XPHOZAH target. $ARDX fell 17.9% the next day, closing at $4.00.
Based on these events, $ARDX investors filed a claim against Ardelyx, alleging the company:
It overstated its ability to overcome payer and patient-access barriers.
It failed to disclose that stricter payer requirements were slowing new-patient starts and prescription fulfillment.
It maintained revenue and growth targets despite access challenges that allegedly undermined those projections.
Investors argue Ardelyx misled the market about patient access and its ability to achieve IBSRELA and XPHOZAH growth targets, causing losses when the truth emerged.